Express Scripts excludes rare disease drugs Onpattro, Ingrezza

Express Scripts excluded from its 2019 preferred formulary two rare disease therapy, Alnylam's amyloidosis drug Onpattro patisiran and Neurocrine's tardive dyskinesia drug Ingrezza valbenazine. Each are one of two approved drugs in their respective indications.

Beginning July 1, Ingrezza from Neurocrine Biosciences Inc. (NASDAQ:NBIX) will not be covered under the formulary, while the other drug approved for tardive dyskinesia, Austedo deutetrabenazine from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), is listed as the preferred alternative...